Studies blood and tissue samples from adults with prostate or bladder cancer
Studies samples from adults whose prostate or bladder cancer has returned or spread.
Key facts
- Who runs it
- University of Washington
- Where
- Seattle, United StatesSee the site
- Trial code
- Registry title
- Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- Aug 2009
- Expected to end
- 31 Jan 2029
- Type of study
- Observational
- Treatments tested
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
- Record updated
- 6 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate or bladder/urothelial cancer that is local or has spread, so that blood and tissue samples can be collected and studied. Men without cancer can also give blood or normal tissue.
- Age
- 18 Years or older
- Sex
- Men only
- Disease stage
- Localized or metastatic bladder/urothelial or prostate cancer, with disease in the primary organ or in bone or soft tissue sites that can be biopsied with minimal risk.
- Earlier treatment
- Cannot have had a VEGF inhibitor (such as Avastin) within the past 28 days.
Main reasons for not taking part
- Cannot stop chronic warfarin or Lovenox for less than 3 days
- Serious or uncontrolled infection
- VEGF inhibitor (such as Avastin) treatment within the past 28 days
- History of excessive unexplained bleeding from previous surgery
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured
- Ability to adequately understand and give informed consent
- Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study
- Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured
- Platelet count > 50,000
- White blood cell (WBC) > 1,500
- Hemoglobin (Hgb) > 8.0
- International normalized ratio (INR) < 1.5
- Partial thromboplastin time (PTT) < 45
- No history of excessive unexplained bleeding from previous surgery
Who cannot take part
- Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days
- Serious or uncontrolled infection
- Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Robert B. MontgomeryTaking people
About the trial
What the trial wants to find out
This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.
The group in the trial
- Ancillary-correlative (blood and tissue collection)
Patients undergo collection of blood and tissue samples for analysis via mutation mapping, DNA sequencing, gene expression microarray, and gene profiling.
Treatment: Cytology Specimen Collection Procedure and Laboratory Biomarker Analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
- Plain-language title
- Studies blood and tissue samples from adults with prostate or bladder cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 August 2026